Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 200-Day Moving Average of $6.98 (2024)

Posted by ABMN Staff on May 15th, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $6.98 and traded as low as $5.08. Aurinia Pharmaceuticals shares last traded at $5.20, with a volume of 1,441,524 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AUPH shares. Jefferies Financial Group lowered their target price on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating on the stock in a research note on Friday, February 16th. StockNews.com upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Royal Bank of Canada reduced their target price on shares of Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, March 1st. Finally, Cantor Fitzgerald cut their price target on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Get Our Latest Stock Report on AUPH

Aurinia Pharmaceuticals Trading Up 3.6 %

The stock has a 50 day moving average of $5.10 and a two-hundred day moving average of $6.98. The company has a quick ratio of 5.05, a current ratio of 5.60 and a debt-to-equity ratio of 0.19.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The firm had revenue of $45.10 million for the quarter, compared to the consensus estimate of $45.00 million. Aurinia Pharmaceuticals had a negative return on equity of 15.06% and a negative net margin of 32.69%. Aurinia Pharmaceuticals’s quarterly revenue was up 58.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.18) earnings per share. On average, research analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.15 EPS for the current year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Patten & Patten Inc. TN bought a new position in Aurinia Pharmaceuticals in the 1st quarter worth approximately $386,000. Vanguard Group Inc. increased its position in Aurinia Pharmaceuticals by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock worth $7,673,000 after acquiring an additional 21,119 shares during the period. Jupiter Asset Management Ltd. raised its stake in Aurinia Pharmaceuticals by 21.3% during the 1st quarter. Jupiter Asset Management Ltd. now owns 247,052 shares of the biotechnology company’s stock valued at $1,238,000 after purchasing an additional 43,366 shares during the last quarter. ProShare Advisors LLC raised its stake in Aurinia Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 2,873 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in Aurinia Pharmaceuticals by 196.1% in the 1st quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock valued at $1,750,000 after purchasing an additional 231,260 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.